KalVista Pharmaceuticals Welcomes New Board Member
TipRanksApr 22 17:13 ET
KalVista Pharmaceuticals: Fairey Was Most Recently Chief Comml Officer at MyoKardia >KALV
KalVista Pharmaceuticals: Fairey Was Most Recently Chief Comml Officer at MyoKardia >KALV
Dow JonesApr 22 06:35 ET
KalVista Pharmaceuticals Appoints William C. Fairey to Bd of Directors >KALV
KalVista Pharmaceuticals Appoints William C. Fairey to Bd of Directors >KALV
Dow JonesApr 22 06:30 ET
KalVista Pharmaceuticals Appoints William C. Fairey to Board of Directors
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--Apr. 22, 2024-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, an
KalVista PharmaceuticalsApr 22 00:00 ET
Needham Reiterates Buy on KalVista Pharma, Maintains $35 Price Target
Needham analyst Serge Belanger reiterates KalVista Pharma with a Buy and maintains $35 price target.
Analyst UpgradesApr 11 06:07 ET
ARS Pharmaceuticals, Nuvalent, and More Stocks See Action From Activist Investors -- Barrons.com
These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity's attaining more than 5% in any class of a company's securities. Subsequen
Barron'sApr 5 18:30 ET
KalVista Pharmaceuticals to Present at 23rd Annual Needham Virtual Healthcare Conference
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--Apr. 3, 2024-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and
KalVista PharmaceuticalsApr 3 00:00 ET
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--Apr. 2, 2024-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista's board of directors g
KalVista PharmaceuticalsApr 2 00:00 ET
Express News | HC Wainwright & Co. Reiterates Buy on KalVista Pharma, Maintains $24 Price Target
Moomoo 24/7Mar 12 06:56 ET
Express News | KalVista Pharmaceuticals Announced The UK Medicines And Healthcare Products Regulatory Agency Has Awarded The Promising Innovative Medicine Designation For Sebetralstat For On-demand Treatment Of Hereditary Angioedema
Moomoo 24/7Mar 12 06:38 ET
Buy Rating on KalVista Pharmaceuticals Backed by Sebetralstat's Breakthrough in HAE Treatment
TipRanksMar 12 06:26 ET
KalVista Pharmaceuticals Awarded UK Promising Innovative Medicine (PIM) Designation for Sebetralstat
– Full EAMS designation would allow treatment of patients with sebetralstat prior to receiving a Marketing Authorization from UK– CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--Mar. 12, 2024
KalVista PharmaceuticalsMar 12 00:00 ET
KalVista Pharmaceuticals Is Maintained at Buy by Needham
KalVista Pharmaceuticals Is Maintained at Buy by Needham
Dow JonesMar 11 16:02 ET
Express News | Needham Maintains Buy on KalVista Pharma, Maintains $35 Price Target
Moomoo 24/7Mar 11 15:52 ET
KalVista Pharma Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/11/2024 162.17% Needham $35 → $35 Maintains Buy 02/14/2024 79.78% HC Wainwright & Co. $16 → $24 Maintai
BenzingaMar 11 15:51 ET
Buy Rating Affirmed for KalVista Pharmaceuticals on Strong Phase 3 Results and Solid Financial Position
TipRanksMar 11 14:45 ET
Recap: KalVista Pharma Q3 Earnings
KalVista Pharma (NASDAQ:KALV) reported its Q3 earnings results on Monday, March 11, 2024 at 06:30 AM.Here's what investors need to know about the announcement.EarningsKalVista Pharma missed estimated
BenzingaMar 11 09:30 ET
KalVista Pharmaceticals GAAP EPS of -$0.84 Misses by $0.07
Seeking AlphaMar 11 06:37 ET
KalVista Pharmaceuticals 3Q Loss/Shr 84c >KALV
KalVista Pharmaceuticals 3Q Loss/Shr 84c >KALV
Dow JonesMar 11 06:30 ET
Press Release: KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update
KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update - Sebetralstat Phase 3 KONFIDENT clinical trial met all endpoints and demonstrated a favorable safety pro
Dow JonesMar 11 06:30 ET
No Data
No Data